Its expression is reduced, for instance, in urothelialbladder cancer and nonsmall cell lungcancer but increased in epithelial ovariancancer and prostate cancer. In both instances where RBM3 is upregulated,this correlates with a favorable prognosis. This evidence concerns the gene RBM3 and Familial prostate cancer.